Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
Brain Injury
|
February 6, 2025
Acoustic neuromodulation with or without micro-voltage tACS reduces post-concussive symptoms
Catherine L Tegeler, Thaddeus J Haight, Wesley R Cole, et al.
Oncogene
|
November 14, 2012
Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model
T Berger, T Ueda, E Arpaia, et al.
Gynecologic Oncology Reports
|
April 21, 2023
Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Monica D Levine, David M O'Malley, Paulina J Haight, et al.
Gynecologic Oncology
|
June 5, 2024
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84]
Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology
|
March 30, 2024
RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer
Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Pharmacotherapy
|
April 23, 2014
The need for PGY2-trained clinical pharmacy specialists
Kelly R Ragucci, Cindy L O'Bryant, Kristin Bova Campbell, et al.
Gynecologic Oncology Reports
|
February 23, 2024
Learning to lead: The evolution of a pilot leadership curriculum for gynecologic oncology fellows at the Ohio State University
Monica D Levine, Vincent M Wagner, Courtney J Riedinger, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
|
November 1, 2014
Brain Volume as an Integrated Marker for the Risk of Death in a Community-Based Sample: Age Gene/Environment Susceptibility--Reykjavik Study
Saskia S G C Van Elderen, Qian Zhang, Sigudur Sigurdsson, et al.
Gynecologic Oncology
|
June 1, 2025
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy
Quinn Kistenfeger, Paulina J Haight, Monica Levine, et al.
Gynecologic Oncology
|
September 23, 2023
The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer
Paulina J Haight, Quinn Kistenfeger, Courtney J Riedinger, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
Brain Injury
|
February 6, 2025
Acoustic neuromodulation with or without micro-voltage tACS reduces post-concussive symptoms
Catherine L Tegeler, Thaddeus J Haight, Wesley R Cole, et al.
Oncogene
|
November 14, 2012
Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model
T Berger, T Ueda, E Arpaia, et al.
Gynecologic Oncology Reports
|
April 21, 2023
Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Monica D Levine, David M O'Malley, Paulina J Haight, et al.
Gynecologic Oncology
|
June 5, 2024
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84]
Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology
|
March 30, 2024
RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer
Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Pharmacotherapy
|
April 23, 2014
The need for PGY2-trained clinical pharmacy specialists
Kelly R Ragucci, Cindy L O'Bryant, Kristin Bova Campbell, et al.
Gynecologic Oncology Reports
|
February 23, 2024
Learning to lead: The evolution of a pilot leadership curriculum for gynecologic oncology fellows at the Ohio State University
Monica D Levine, Vincent M Wagner, Courtney J Riedinger, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences
|
November 1, 2014
Brain Volume as an Integrated Marker for the Risk of Death in a Community-Based Sample: Age Gene/Environment Susceptibility--Reykjavik Study
Saskia S G C Van Elderen, Qian Zhang, Sigudur Sigurdsson, et al.
Gynecologic Oncology
|
June 1, 2025
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy
Quinn Kistenfeger, Paulina J Haight, Monica Levine, et al.
Gynecologic Oncology
|
September 23, 2023
The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer
Paulina J Haight, Quinn Kistenfeger, Courtney J Riedinger, et al.
Page
of 8